MIRM
$88.51-2.21 (-2.44%)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
Recent News
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Mirum Pharmaceuticals (MIRM) Completes Enrollment for Phase 3 EXPAND Study of LIVMARLI
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the most promising stocks under $100 to buy. On March 16, Mirum Pharmaceuticals announced the completion of enrollment for its Phase 3 EXPAND study, which evaluates the efficacy and safety of LIVMARLI (maralixibat) in treating cholestatic pruritus. This randomized, double-blind, placebo-controlled trial focuses on patients aged 6 months […]
Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap
Mirum Pharmaceuticals (NasdaqGM:MIRM) has completed enrollment in the Phase 3 EXPAND study of LIVMARLI. The EXPAND trial is designed to support a potential label expansion for treating cholestatic pruritus across a broader range of rare cholestatic liver diseases, including biliary atresia. This represents a key corporate milestone as the company progresses a pivotal program aimed at addressing a wider patient population with unmet needs. Mirum Pharmaceuticals focuses on therapies for rare...
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.